» Articles » PMID: 33316368

Changes in the Brain Transcriptome After DNA Aβ42 Trimer Immunization in a 3xTg-AD Mouse Model

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2020 Dec 14
PMID 33316368
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) has been associated with accumulation of amyloid beta (Aβ) peptides in brain, and immunotherapy targeting Aβ provides potential for AD prevention. We have used a DNA Aβ42 trimer construct for immunization of 3xTg-AD mice and found previously significant reduction of amyloid and tau pathology due to the immunotherapy. We show here that DNA Aβ42 immunized 3xTg-AD mice showed better performance in nest building activities and had a higher 24 months survival rate compared to the non-treated AD controls. The analysis of differently expressed genes in brains from 24 months old mice showed significant increases transcript levels between non-immunized AD mice and wild-type controls for genes involved in microglia and astrocyte function, cytokine and inflammatory signaling, apoptosis, the innate and adaptive immune response and are consistent with an inflammatory phenotype in AD. Most of these upregulated genes were downregulated in the DNA Aβ42 immunized 3xTg-AD mice due to the vaccine. Transcript numbers for the immediate early genes, Arc, Bdnf, Homer1, Egr1 and cfos, involved in neuronal and neurotransmission pathways which were much lower in the non-immunized 3xTg-AD mice, were restored to wild-type mouse brain levels in DNA Aβ42 immunized 3xTg-AD mice indicating positive effects of DNA Aβ42 immunotherapy on synapse stability and plasticity. The immune response after immunization is complex, but the multitude of changes after DNA Aβ42 immunization shows that this response moves beyond the amyloid hypothesis and into direction of disease prevention.

Citing Articles

Modulation of hippocampal protein expression by a brain penetrant biologic TNF-α inhibitor in the 3xTg Alzheimer's disease mice.

Jagadeesan N, Roules G, Chandrashekar D, Yang J, Kolluru S, Sumbria R J Transl Med. 2024; 22(1):291.

PMID: 38500108 PMC: 10946165. DOI: 10.1186/s12967-024-05008-x.


Neurotrophin-3 from the dentate gyrus supports postsynaptic sites of mossy fiber-CA3 synapses and hippocampus-dependent cognitive functions.

Tan J, An J, Deane H, Xu H, Liao G, Xu B Mol Psychiatry. 2024; 29(4):1192-1204.

PMID: 38212372 PMC: 11176039. DOI: 10.1038/s41380-023-02404-5.


Glial cell transcriptome analyses in 3xTg-AD mice: Effects of aging, disease progression, and anti-Aβ immunotherapy.

Lambracht-Washington D, Fu M, Manouchehri N, Hynan L, Stuve O, Rosenberg R Aging Brain. 2023; 3:100066.

PMID: 36911262 PMC: 9997156. DOI: 10.1016/j.nbas.2023.100066.

References
1.
Xiao M, Xu D, Craig M, Pelkey K, Chien C, Shi Y . NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife. 2017; 6. PMC: 5404919. DOI: 10.7554/eLife.23798. View

2.
Karran E, De Strooper B . The amyloid cascade hypothesis: are we poised for success or failure?. J Neurochem. 2016; 139 Suppl 2:237-252. DOI: 10.1111/jnc.13632. View

3.
Preuss C, Pandey R, Piazza E, Fine A, Uyar A, Perumal T . A novel systems biology approach to evaluate mouse models of late-onset Alzheimer's disease. Mol Neurodegener. 2020; 15(1):67. PMC: 7656729. DOI: 10.1186/s13024-020-00412-5. View

4.
Bellanti F, Iannelli G, Blonda M, Tamborra R, Villani R, Romano A . Alterations of Clock Gene RNA Expression in Brain Regions of a Triple Transgenic Model of Alzheimer's Disease. J Alzheimers Dis. 2017; 59(2):615-631. PMC: 5523844. DOI: 10.3233/JAD-160942. View

5.
Matsumoto Y, Niimi N, Kohyama K . Development of a new DNA vaccine for Alzheimer disease targeting a wide range of aβ species and amyloidogenic peptides. PLoS One. 2013; 8(9):e75203. PMC: 3785508. DOI: 10.1371/journal.pone.0075203. View